Which bacterial process does tigecycline target in mrsa?

Which bacterial process does tigecycline target in MRSA?
Tigecycline stops protein synthesis in MRSA by binding to the 30S ribosomal subunit and blocking aminoacyl-tRNA from entering the A site.

How does tigecycline act differently from classic tetracycline antibiotics?
Tigecycline binds the ribosome with higher affinity and evades the Tet(M) ribosomal-protection proteins and efflux pumps that confer resistance in most MRSA isolates.

Why is tigecycline active against MRSA strains that resist other tetracyclines?
Its C9 side-chain modification keeps it from being expelled or displaced by Tet(M), so even isolates already resistant to doxycycline or minocycline remain susceptible.

What clinical situations prompt doctors to choose tigecycline for MRSA infections?
Clinicians turn to tigecycline when the isolate shows resistance to vancomycin or linezolid, or when the patient cannot tolerate beta-lactams or glycopeptides.

When does tigecycline patent protection end and what follows?
Tigecycline’s composition-of-matter patent expired in 2020; generic versions entered the U.S. market after 2021 [1].

Who manufactures the original brand-name version?
Pfizer markets tigecycline as Tygacil.

How long does the FDA-approved label indicate tigecycline should be administered?
The approved duration ranges from 5 to 14 days, usually guided by infection site and clinical response.

What side effects are patients and clinicians most concerned about?
Nausea, vomiting, and a possible increase in all-cause mortality have driven most of the caution surrounding its use.

Can biosimilars or generics compete with Tygacil before the exclusivities end?
No true biosimilars exist; ordinary generic small-molecule copies became available after the main patent lapsed.